Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II–III TN BC in...
Main Authors: | O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-11-01
|
Series: | Opuholi Ženskoj Reproduktivnoj Sistemy |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/732 |
Similar Items
-
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
by: O A Pavlikova, et al.
Published: (2017-12-01) -
Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01) -
Ribociclib in 1st line HR+ breast cancer treatment
by: L G Zhukova, et al.
Published: (2018-06-01) -
EFFECTIVENESS OF MOLECULAR-GENETIC DIAGNOSTICS DURING PERTUSSIS INFECTION FOCI EXAMINATION
by: A. S. Pimenova, et al.
Published: (2017-06-01) -
Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)